PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new
 PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. |
Data collected by the Synercid Microbiology Assessment of Resistance Trends (SMART)--a surveillance project run by the State University of New York (SUNY) at Buffalo and the University of Iowa College of Medicine--show increasing drug resistance in the United States. More than 31 percent of 17,000 bacterial isolates ...
Memory-enhancing neural networks may also drive involuntary musical loops in the brain.
View this Issue
In this webinar, learn how scientists use advanced human brain models to uncover treatment strategies for complex neurological conditions.
Modern DNA synthesis platforms empower researchers to explore the molecular world, from next-generation sequencing to cell and gene therapy development.
An improved chromatography membrane elution method helps scientists achieve higher yields of pure plasmid DNA.
By fine-tuning polishing conditions, scientists attain high titers of infectious lentiviral particles during purification.
This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.
New fluidics and clog detection systems further simplify operation and reduce instrument downtime
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies
Study identifies new metrics to enhance scRNA-seq based virtual cell modelling
